Valuation: Satellos Bioscience Inc.

Market Cap 152M 137M 125M 114M 215M 14.32B 221M 1.5B 600M 7.64B 572M 559M 24.12B P/E 2026 *
-3.05x
P/E 2027 * -2.97x
Enterprise Value 50.7M 45.48M 41.56M 37.94M 71.48M 4.77B 73.73M 501M 200M 2.54B 190M 186M 8.03B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.63%
Yield 2026 *
-
Yield 2027 * -
1 day+12.20%
1 week+6.08%
Current month+6.08%
1 month-6.04%
3 months-29.62%
6 months-3.16%
Current year+27.78%
1 week 8.65
Extreme 8.65
10.49
1 month 8.65
Extreme 8.65
11.64
Current year 7.67
Extreme 7.67
18.98
1 year 7.56
Extreme 7.560003
18.98
3 years 3.48
Extreme 3.480001
18.98
5 years 2.58
Extreme 2.580001
18.98
10 years 2.58
Extreme 2.580001
22.8
Manager TitleAgeSince
Chief Executive Officer 70 28/02/2018
Chief Tech/Sci/R&D Officer - 30/04/2018
Director of Finance/CFO - 31/08/2023
Director TitleAgeSince
Chairman 59 30/06/2018
Director/Board Member 50 28/02/2018
Director/Board Member 70 30/06/2012
Date Insider Type Main position Quantity % Market Cap. Importance
18/08/26 Option

Director

10,608 0.0509%
18/08/26 Option

Director

10,608 0.0509%
18/08/26 Option

Director

10,608 0.0509%
Change 5-day change 1-year change 3-year change Capi.($)
+12.20%+6.08%+24.02%+140.95% 152M
-4.83%+3.51%+53.62%+61.75% 65.94B
-1.34%+2.98%+24.79%+100.18% 56.53B
+0.02%+1.07%+10.63%+76.66% 56.88B
+5.09%+9.89%+22.45%+107.48% 46.49B
+2.62%+1.68%+28.91%+37.01% 44.8B
+8.24%+0.51%+213.26%+792.66% 41.59B
-1.86%+10.13%+26.82%+53.22% 35.35B
-2.97%-9.84%+88.86%+76.17% 33.29B
-2.18%+7.06%+36.06%-4.95% 24.92B
Average +1.50%+3.54%+52.94%+144.11% 40.59B
Weighted average by Cap. +0.21%+3.40%+53.11%+142.96%

Financials

2026 *2027 *
Net sales - -
Net income -49.92M -44.77M -40.92M -37.35M -70.37M -4.69B -72.59M -493M -197M -2.5B -187M -183M -7.9B -65.51M -58.75M -53.69M -49.01M -92.35M -6.16B -95.26M -647M -258M -3.29B -246M -241M -10.37B
Net Debt -102M -91.13M -83.28M -76.02M -143M -9.55B -148M -1B -400M -5.1B -381M -373M -16.09B -119M -107M -97.54M -89.04M -168M -11.19B -173M -1.18B -469M -5.97B -447M -437M -18.84B
Projected Income Statement - Annual - Satellos Bioscience Inc.
Logo Satellos Bioscience Inc.
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Employees
20
Date Price Change Volume
06/11/26 CA$10.12 +12.20% 29,021
05/11/26 CA$9.020 -3.11% 34,191
04/11/26 CA$9.310 +3.44% 401
03/11/26 CA$9.000 -0.55% 7,819
02/11/26 CA$9.050 -5.14% 826
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Satellos Bioscience Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
10.12CAD
Average target price
17.47CAD
Spread / Average Target
+72.66%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Satellos Bioscience Inc.
  1. Stock Market
  2. Stocks
  3. MSCL Stock